Insulin-like growth factor 1 and prostate cancer risk: A population- based, case-control study

Journal of the National Cancer Institute

Volumn 90, Issue 12, 1998, Pages 911-915

  Wolk, Alicja ^a   Mantzoros, Christos S ^b,c   Andersson, Swen Olof ^d   Bergström, Reinhold ^a   Signorello, Lisa B ^e   Lagiou, Pagona ^b   Adami, Hans Olov ^d,e   Trichopoulos, Dimitrios ^e  

^a KAROLINSKA INSTITUTE   (Sweden)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d ÖREBRO MEDICAL CENTRE HOSPITAL   (Sweden)

^e HARVARD CENTER FOR CANCER PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

AGED; ARTICLE; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PROSTATE BIOPSY; PROSTATE CANCER; REGRESSION ANALYSIS; SWEDEN;

EID: 0032540667     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.12.911     Document Type: Article

References (23)

1. Montie JE, Pienta KJ. Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer. Urology 1994;43:892-9.
2. Nomura A, Heilbrun LK, Stemmerman GN, Judd HL. Prediagnostic serum hormones and the risk of prostate cancer. Cancer Res 1988; 48:3515-7.
3. Barrett-Connor E, Garland C, McPhillips JB, Khaw KT, Wingard DL. A prospective, population-based study of androstenedione, estrogens, and prostate cancer. Cancer Res 1990;50: 169-73.
4. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996;88:1118-26.
5. Iwamura M, Sluss PM, Casamento JB, Cockett AT. Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines. Prostate 1993;22:243-52.
6. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Eur Urol 1995; 27 Suppl 2:45-7.
7. Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 1997;76:1115-8.
8. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-6.
9. Andersson SO, Adami HO, Bergstrom R, Wide L. Serum pituitary and sex steroid hormone levels in the etiology of prostatic cancer - a population-based case-control study. Br J Cancer 1993;68:97-102.
10. Andersson SO, Baron J, Bergstrom R, Lindgren C, Wolk A, Adami HO. Lifestyle factors and prostate cancer risk: a case-control study in Sweden. Cancer Epidemiol Biomarkers Prev 1996;5:509-13.
11. Union Internationale Contre le Cancer. TNM Classification of Tumours, 3rd ed. Geneva, Switzerland: International Union Against Cancer, 1978.
12. Thierry van Dessel HJ, Chandrasekher Y, Yap OW, Lee PD, Hintz RL, Faessen GH, et al. Serum and follicular fluid levels of insulin-like growth factor I (IGF-I), IGF-II, and IGF-binding protein-1 and -3 during the normal menstrual cycle. J Clin Endocrinol Metab 1996;81:1224-31.
13. Breslow NE, Day NE. Statistical methods in cancer research, volume I - The analysis of case-control studies. IARC Sci Publ 1980;32: 5-338.
14. Le Roith D. Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N Engl J Med 1997;336: 633-40.
15. Rajah R, Valetinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta 1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 1997;272:12181-8.
16. Goodman-Gruen D, Barrett-Connor E. Epidemiology of insulin-like growth factor-I in elderly men and women. Am J Epidemiol 1997; 145:970-6.
17. Cohen P, Peehl DM, Lamson G, Rosenfeld RG. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab 1991;73:401-7.
18. Kimura G, Kasuya J, Giannini S, Honda Y, Mohan S, Kawachi M, et al. Insulin-like growth factor (IGF) system components in human prostatic cancer cell-lines: LNCaP, DU145, and PC-3 cells. Int J Urol 1996;3: 39-46.
19. La Vecchia C, Negri E, Parazzini F, Boyle P, D'Avanzo B, Levi F, et al. Height and cancer risk in a network of case-control studies from northern Italy. Int J Cancer 1990;45:275-9.
20. Hebert PR, Ajani U, Cook NR, Lee IM, Chan KS, Hennekens CH. Adult height and incidence of cancer in male physicians (United States). Cancer Causes Control 1997;8: 591-7.
21. Juul A, Bang P, Hertel NT, Main K, Dalgaard P, Jorgensen K, et al. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 1994;78: 744-52.
22. Andersson SO, Wolk A, Bergström R, Giovannucci E, Lindgren C, Baron J, et al. Energy, nutrient intake and prostate cancer risk: a population-based case-control study in Sweden. Int J Cancer 1996;68:716-22.
23. Dunn SE, Kari FW, French J, Leininger JR, Travlos G, Wilson R, et al. Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res 1997;57:4667-72.